唐氏综合征患儿急性淋巴细胞白血病的移植结果。
Outcome of transplantation for acute lymphoblastic leukemia in children with Down syndrome.
机构信息
The Hospital for Sick Children, University of Toronto, Toronto, Ontario, Canada.
出版信息
Pediatr Blood Cancer. 2014 Jun;61(6):1126-8. doi: 10.1002/pbc.24918. Epub 2014 Jan 4.
Abstract
We report on 27 patients with Down syndrome (DS) and acute lymphoblastic leukemia (ALL) who received allogeneic hematopoietic cell transplantation (HCT) between 2000 and 2009. Seventy-eight percent of patients received myeloablative conditioning and 52% underwent transplantation in second remission. Disease-free survival (DFS) was 24% at a median of 3 years. Post-transplant leukemic relapse was more frequent than expected for children with DS-ALL (54%) than for non-DS ALL. These data suggest leukemic relapse rather than transplant toxicity is the most important cause of treatment failure. Advancements in leukemia control are especially needed for improvement in HCT outcomes for DS-ALL.
摘要
我们报告了 27 例唐氏综合征（DS）合并急性淋巴细胞白血病（ALL）患者，他们在 2000 年至 2009 年间接受了异基因造血细胞移植（HCT）。78%的患者接受了清髓性预处理，52%的患者在第二次缓解期进行了移植。中位随访 3 年后，无病生存率（DFS）为 24%。移植后白血病复发的频率高于预期，DS-ALL 患者（54%）高于非-DS ALL 患者。这些数据表明，白血病复发而不是移植毒性是治疗失败的最重要原因。白血病控制的进展对于改善 DS-ALL 的 HCT 结果尤为重要。
相似文献
1
Outcome of transplantation for acute lymphoblastic leukemia in children with Down syndrome.
Pediatr Blood Cancer. 2014 Jun;61(6):1126-8. doi: 10.1002/pbc.24918. Epub 2014 Jan 4.
2
A Single-Center Experience With Hematopoietic Stem Cell Transplantation for Pediatric Acute Lymphoblastic Leukemia: A Modest Pitch for Non-Total Body Irradiation Conditioning Regimens.
Exp Clin Transplant. 2019 Apr;17(2):243-250. doi: 10.6002/ect.2017.0226. Epub 2018 Oct 5.
3
Allogeneic hematopoietic cell transplantation (allogeneic HCT) for treatment of pediatric Philadelphia chromosome-positive acute lymphoblastic leukemia (ALL).
Pediatr Blood Cancer. 2009 Dec 15;53(7):1289-94. doi: 10.1002/pbc.22263.
4
Allogeneic haematopoietic stem cell transplantation for infant acute lymphoblastic leukaemia with KMT2A (MLL) rearrangements: a retrospective study from the paediatric acute lymphoblastic leukaemia working group of the Japan Society for Haematopoietic Cell Transplantation.
Br J Haematol. 2015 Feb;168(4):564-70. doi: 10.1111/bjh.13174. Epub 2014 Oct 10.
5
Transplant Outcomes for Children with T Cell Acute Lymphoblastic Leukemia in Second Remission: A Report from the Center for International Blood and Marrow Transplant Research.
Biol Blood Marrow Transplant. 2015 Dec;21(12):2154-2159. doi: 10.1016/j.bbmt.2015.08.023. Epub 2015 Aug 29.
6
Stem-cell transplantation in children with acute lymphoblastic leukemia: A prospective international multicenter trial comparing sibling donors with matched unrelated donors-The ALL-SCT-BFM-2003 trial.
J Clin Oncol. 2015 Apr 10;33(11):1265-74. doi: 10.1200/JCO.2014.58.9747. Epub 2015 Mar 9.
7
Favorable outcome of unrelated cord blood transplantation for Philadelphia chromosome-positive acute lymphoblastic leukemia.
Biol Blood Marrow Transplant. 2011 Jul;17(7):1093-7. doi: 10.1016/j.bbmt.2011.01.010. Epub 2011 Jan 28.
8
9
Allogeneic hematopoietic cell transplantation in children with relapsed acute lymphoblastic leukemia isolated to the central nervous system.
Biol Blood Marrow Transplant. 2008 Jun;14(6):685-92. doi: 10.1016/j.bbmt.2008.03.011.
10
Similar outcome of allogeneic stem cell transplantation after myeloablative and sequential conditioning regimen in patients with refractory or relapsed acute myeloid leukemia: A study from the Société Francophone de Greffe de Moelle et de Thérapie Cellulaire.
Am J Hematol. 2018 Mar;93(3):416-423. doi: 10.1002/ajh.25004. Epub 2018 Jan 8.
引用本文的文献
1
Calcineurin inhibition may prevent Alzheimer disease in people with Down syndrome.
Alzheimers Dement. 2025 Mar;21(3):e70034. doi: 10.1002/alz.70034.
2
Inotuzumab ozogamicin for relapse prevention in a boy with Down syndrome and relapsed acute lymphoblastic leukemia.
Int J Hematol. 2025 Feb;121(2):276-280. doi: 10.1007/s12185-024-03890-1. Epub 2024 Dec 9.
3
CAR-T treatment is safe and effective in adult patients with Down syndrome and B-cell acute lymphoblastic leukemia (B-ALL).
Bone Marrow Transplant. 2024 Nov;59(11):1611-1613. doi: 10.1038/s41409-024-02386-0. Epub 2024 Aug 9.
4
Down syndrome-associated leukaemias: current evidence and challenges.
Ther Adv Hematol. 2024 Jul 23;15:20406207241257901. doi: 10.1177/20406207241257901. eCollection 2024.
5
The Implementation of Chimeric Antigen Receptor (CAR) T-cell Therapy in Pediatric Patients: Where Did We Come From, Where Are We Now, and Where are We Going?
Clin Hematol Int. 2024 Mar 13;6(1):96-115. doi: 10.46989/001c.94386. eCollection 2024.
6
Bispecific Antibodies and Other Non-CAR Targeted Therapies and HSCT: Decreased Toxicity for Better Transplant Outcome in Paediatric ALL?
Front Pediatr. 2022 Feb 2;9:795833. doi: 10.3389/fped.2021.795833. eCollection 2021.
7
Allogeneic Hematopoietic Stem Cell Transplantation for Children With Acute Lymphoblastic Leukemia: Shifting Indications in the Era of Immunotherapy.
Front Pediatr. 2021 Dec 23;9:782785. doi: 10.3389/fped.2021.782785. eCollection 2021.
8
Immunotherapy in Pediatric B-Cell Acute Lymphoblastic Leukemia: Advances and Ongoing Challenges.
Paediatr Drugs. 2020 Oct;22(5):485-499. doi: 10.1007/s40272-020-00413-3.
9
Gain of chromosome 21 in hematological malignancies: lessons from studying leukemia in children with Down syndrome.
Leukemia. 2020 Aug;34(8):1984-1999. doi: 10.1038/s41375-020-0854-5. Epub 2020 May 20.
10
CD19 CAR T Cells for the Treatment of Pediatric Pre-B Cell Acute Lymphoblastic Leukemia.
Paediatr Drugs. 2020 Feb;22(1):1-11. doi: 10.1007/s40272-019-00370-6.
本文引用的文献
1
Outcomes of treatment for relapsed acute lymphoblastic leukaemia in children with Down syndrome.
Br J Haematol. 2013 Jul;162(1):98-106. doi: 10.1111/bjh.12348. Epub 2013 Apr 18.
2
Outcome of transplantation for acute myelogenous leukemia in children with Down syndrome.
Biol Blood Marrow Transplant. 2013 Jun;19(6):893-7. doi: 10.1016/j.bbmt.2013.02.017. Epub 2013 Mar 1.
3
Outcomes after induction failure in childhood acute lymphoblastic leukemia.
N Engl J Med. 2012 Apr 12;366(15):1371-81. doi: 10.1056/NEJMoa1110169.
4
No difference in outcome between children and adolescents transplanted for acute lymphoblastic leukemia in second remission.
Blood. 2011 Dec 15;118(25):6683-90. doi: 10.1182/blood-2011-05-354233. Epub 2011 Oct 18.
5
Acute lymphoblastic leukaemia in children with Down syndrome: an updated review.
Br J Haematol. 2011 Nov;155(4):420-5. doi: 10.1111/j.1365-2141.2011.08846.x. Epub 2011 Sep 21.
6
Effect of mitoxantrone on outcome of children with first relapse of acute lymphoblastic leukaemia (ALL R3): an open-label randomised trial.
Lancet. 2010 Dec 11;376(9757):2009-17. doi: 10.1016/S0140-6736(10)62002-8. Epub 2010 Dec 3.
7
Outcomes of pediatric bone marrow transplantation for leukemia and myelodysplasia using matched sibling, mismatched related, or matched unrelated donors.
Blood. 2010 Nov 11;116(19):4007-15. doi: 10.1182/blood-2010-01-261958. Epub 2010 Jul 29.
8
Long-term outcome in children with relapsed acute lymphoblastic leukemia after time-point and site-of-relapse stratification and intensified short-course multidrug chemotherapy: results of trial ALL-REZ BFM 90.
J Clin Oncol. 2010 May 10;28(14):2339-47. doi: 10.1200/JCO.2009.25.1983. Epub 2010 Apr 12.
9
Relapse, not regimen-related toxicity, was the major cause of treatment failure in 11 children with Down syndrome undergoing haematopoietic stem cell transplantation for acute leukaemia.
Bone Marrow Transplant. 2007 Nov;40(10):945-9. doi: 10.1038/sj.bmt.1705844. Epub 2007 Sep 3.
10
Unrelated donor stem cell transplantation compared with chemotherapy for children with acute lymphoblastic leukemia in a second remission: a matched-pair analysis.
Blood. 2003 May 15;101(10):3835-9. doi: 10.1182/blood.V101.10.3835.
Zotero 插件